查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586190

細胞免疫治療市場：按類型、按適應症、按技術類型、按最終用途 - 2025-2030 年全球預測

Cellular Immunotherapy Market by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy), Indication (B-Cell Malignancies, Liver Cancer, Prostate Cancer), Technology Type, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

細胞免疫治療市場2023年估值為112.3億美元，預計2024年將達140.2億美元，複合年成長率為25.34%，預計到2030年將達到546億美元。

細胞免疫療法是癌症治療的前沿領域，它利用人體自身的免疫細胞（例如 T 細胞）來瞄準並摧毀癌細胞。這種方法非常重要，因為它有可能提供高度客製化的治療方法，並且比傳統治療方法的副作用更少。對未滿足關鍵字的需求在於它們能夠解決未滿足的醫療需求，特別是對傳統治療方法有抵抗力的癌症。應用主要集中在腫瘤學領域，重點關注白血病和淋巴瘤等骨髓惡性腫瘤，但正在迅速擴展到包括固態腫瘤和慢性感染疾病。最終用途包括醫院、癌症研究中心和生技公司。該市場受到癌症發病率上升、基因工程技術進步以及研發投資增加的推動。主要成長要素包括對精準醫療的需求不斷增加以及政府對新治療方法的支持和核准。最近 FDA核准CAR T 細胞療法證實了巨大的機遇，並鼓勵相關人員投資 NK 細胞療法和聯合治療等下一代技術。然而，挑戰依然存在，包括複雜的製造流程、高昂的處理成本和監管障礙。也有一些限制，例如潛在的治療相關毒性以及患者接受治療之前的較長前置作業時間。創新應著重於提高治療方法的安全性和有效性、降低製造成本以及增加患者的可近性。開發現成的同種異體移植解決方案和個人化治療方法的研究可能會產生有意義的進展。市場仍然充滿活力，其特點是快速的技術創新和競爭格局，合作和收購頻繁地塑造成長軌跡。公司必須透過建立策略夥伴關係並繼續適應技術變革來利用這些趨勢。透過這樣做，您可以克服挑戰並在這一重要領域建立強大的投資組合。

主要市場統計
基準年[2023] 112.3億美元
預測年份 [2024] 140.2億美元
預測年份 [2030] 546億美元
複合年成長率（%） 25.34%

市場動態：揭示快速發展的細胞免疫治療市場的關鍵市場洞察

供需的動態交互作用正在改變細胞免疫治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 癌症和先進細胞療法的普及
    • 政府積極致力於細胞療法的研發
    • 腫瘤浸潤淋巴細胞（TIL）療法和人工T細胞受體（TCR）療法的擴展
  • 市場限制因素
    • 設備和治療方法的初始成本較高
  • 市場機會
    • 細胞免疫療法相關技術進展及新產品
    • 各種細胞免疫療法藥物的核准增加
  • 市場挑戰
    • 產品召回和嚴格的監管核准

波特五力：駕馭細胞免疫治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解細胞免疫治療市場的外部影響

外部宏觀環境因素在塑造細胞免疫治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解細胞免疫治療市場的競爭格局

對細胞免疫治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣細胞免疫治療市場供應商績效評估

FPNV定位矩陣是評估細胞免疫療法市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了細胞免疫治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，細胞免疫治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症流行和先進的細胞治療方法
      • 政府對細胞療法研究和開發的有利方法
      • 腫瘤浸潤淋巴細胞 (TIL) 和工程化 T 細胞受體 (TCR) 療法的普及率不斷上升
    • 抑制因素
      • 設備和治療方法的初始成本很高
    • 機會
      • 細胞免疫療法的技術進步與新產品
      • 各種基於細胞的免疫療法藥物的核准增加
    • 任務
      • 產品召回和嚴格的監管核准
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章細胞免疫治療市場：依類型

  • CAR-T細胞療法
  • 樹突細胞療法
  • NK細胞療法
  • 腫瘤浸潤淋巴細胞治療

第7章依適應症分類的細胞免疫治療市場

  • B細胞惡性
  • 肝癌
  • 攝護腺癌
  • 腎臟細胞癌

第8章按技術類型分類的細胞免疫治療市場

  • 細胞激素和免疫調節劑
  • 單株抗體

第9章細胞免疫治療市場：依最終用途分類

  • 癌症研究所
  • 醫院

第10章美洲細胞免疫治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區細胞免疫治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲細胞免疫治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Corning Incorporated
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glycostem Therapeutics BV
  • Immatics NV
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics（Shanghai）Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Tessa Therapeutics Ltd.
Product Code: MRR-7C50F2739738

The Cellular Immunotherapy Market was valued at USD 11.23 billion in 2023, expected to reach USD 14.02 billion in 2024, and is projected to grow at a CAGR of 25.34%, to USD 54.60 billion by 2030.

Cellular immunotherapy, a pioneering field within cancer treatment, leverages the body's immune cells, such as T-cells, to target and destroy cancerous cells. This approach is critical due to its potential to offer highly tailored therapies with fewer side effects compared to conventional treatments. The necessity of cellular immunotherapy lies in its capacity to address unmet medical needs, particularly for cancers that are resistant to traditional therapies. Applications are primarily in oncology, focusing on hematological malignancies like leukemia and lymphoma, but it's rapidly expanding into solid tumors and chronic infections. End-use encompasses hospitals, cancer research centers, and biotech firms. The market is driven by a rise in cancer prevalence, technological advancements in genetic engineering, and increasing investments in R&D. Key growth factors include governmental support and approval of new therapies, alongside the escalating demand for precision medicine. Recent FDA approvals of CAR T-cell therapies underscore significant opportunities, urging stakeholders to invest in next-gen technologies like NK-cell therapies and combination treatments. However, challenges persist, such as complex manufacturing processes, high treatment costs, and regulatory hurdles. Limitations also include potential therapy-related toxicity and long lead times to patient availability. Innovation should focus on improving the safety and efficacy of therapies, reducing production costs, and enhancing patient accessibility. Research into developing allogeneic, off-the-shelf solutions and personalized treatment regimens could offer meaningful advancements. The market remains dynamic, characterized by rapid innovation and a competitive landscape, with collaborations and acquisitions frequently shaping growth trajectories. Companies must capitalize on these trends by building strategic partnerships and remaining adaptive to technological shifts. By doing so, they can navigate challenges and ensure robust portfolio development in this critical field.

KEY MARKET STATISTICS
Base Year [2023] USD 11.23 billion
Estimated Year [2024] USD 14.02 billion
Forecast Year [2030] USD 54.60 billion
CAGR (%) 25.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cellular Immunotherapy Market

The Cellular Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancer and advanced cell based therapies
    • Favorable government initiatives for cellular therapies R&D
    • Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
  • Market Restraints
    • High initial costs of devices and therapies
  • Market Opportunities
    • Technological advancements and new products for cellular immunotherapy
    • Increasing approvals of different cell-based immunotherapy drugs
  • Market Challenges
    • Product recalls and stringent regulatory approvals

Porter's Five Forces: A Strategic Tool for Navigating the Cellular Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cellular Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cellular Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cellular Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cellular Immunotherapy Market

A detailed market share analysis in the Cellular Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cellular Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cellular Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cellular Immunotherapy Market

A strategic analysis of the Cellular Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cellular Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Corning Incorporated, Dendreon Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glycostem Therapeutics B.V., Immatics N.V., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., and Tessa Therapeutics Ltd..

Market Segmentation & Coverage

This research report categorizes the Cellular Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, and Tumor-Infiltrating Lymphocytes Therapy.
  • Based on Indication, market is studied across B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
  • Based on Technology Type, market is studied across Cytokines & Immunomodulators and Monoclonal Antibodies.
  • Based on End-Use, market is studied across Cancer Institutes and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer and advanced cell based therapies
      • 5.1.1.2. Favorable government initiatives for cellular therapies R&D
      • 5.1.1.3. Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
    • 5.1.2. Restraints
      • 5.1.2.1. High initial costs of devices and therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements and new products for cellular immunotherapy
      • 5.1.3.2. Increasing approvals of different cell-based immunotherapy drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Product recalls and stringent regulatory approvals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cellular Immunotherapy Market, by Type

  • 6.1. Introduction
  • 6.2. CAR T-Cell Therapy
  • 6.3. Dendritic Cell Therapy
  • 6.4. NK Cell Therapy
  • 6.5. Tumor-Infiltrating Lymphocytes Therapy

7. Cellular Immunotherapy Market, by Indication

  • 7.1. Introduction
  • 7.2. B-Cell Malignancies
  • 7.3. Liver Cancer
  • 7.4. Prostate Cancer
  • 7.5. Renal Cell Carcinoma

8. Cellular Immunotherapy Market, by Technology Type

  • 8.1. Introduction
  • 8.2. Cytokines & Immunomodulators
  • 8.3. Monoclonal Antibodies

9. Cellular Immunotherapy Market, by End-Use

  • 9.1. Introduction
  • 9.2. Cancer Institutes
  • 9.3. Hospitals

10. Americas Cellular Immunotherapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cellular Immunotherapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cellular Immunotherapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptimmune Therapeutics PLC
  • 2. Adicet Bio, Inc.
  • 3. Apac Biotech Private Limited
  • 4. AstraZeneca PLC
  • 5. Atara Biotherapeutics, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celyad Oncology SA
  • 9. Corning Incorporated
  • 10. Dendreon Pharmaceuticals LLC
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche AG
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline PLC
  • 15. Glycostem Therapeutics B.V.
  • 16. Immatics N.V.
  • 17. Inovio Pharmaceuticals, Inc.
  • 18. Iovance Biotherapeutics, Inc.
  • 19. Johnson & Johnson Services, Inc.
  • 20. JW Therapeutics (Shanghai) Co., Ltd.
  • 21. Lonza Group Ltd.
  • 22. Merck KGaA
  • 23. Novartis AG
  • 24. Pfizer Inc.
  • 25. Tessa Therapeutics Ltd.

LIST OF FIGURES

  • FIGURE 1. CELLULAR IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CELLULAR IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELLULAR IMMUNOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023